inclusion criteria: patients with sars-cov-2 infection, confirmed by any validated microbiological technique, and with one or more symptoms associated with covid-19 with ≤5 days of evolution and with an oxygen saturation ≥93% breathing room air. in addition, the patients had to present some risk factor for severe disease: * chronic heart failure (nyha ≥ 2) * arterial hypertension under pharmacological treatment * chronic lung disease: copd (bronchitis, emphysema or chronic obstruction) with dyspnoea at least on moderate exertion, or moderate-severe asthma (that required inhaled corticosteroids to control symptoms or had received systemic corticosteroids during the last year due to decompensation) * chronic renal failure (glomerular filtration rate \<60 ml/min/1.73 m², by ckd- ild) * diabetes mellitus requiring pharmacological treatment or obesity grade ≥ i (bmi ≥30 kg/m2). * patients ≥65 years were included, regardless of other risk factors.

inclusion criteria: patients with sars-cov-2 infection, confirmed by any validated microbiological technique, and with one or more symptoms associated with covid-19 with ≤5 days of evolution and with an oxygen saturation ≥93% breathing room air. in addition, the patients had to present some risk factor for severe disease: * chronic heart failure (nyha ≥ 2) * arterial hypertension under pharmacological treatment * chronic lung disease: copd (bronchitis, emphysema or chronic obstruction) with dyspnoea at least on moderate exertion, or moderate-severe asthma (that required inhaled corticosteroids to control symptoms or had received systemic corticosteroids during the last year due to decompensation) * chronic renal failure (glomerular filtration rate \<60 ml/min/1.73 m², by ckd- ild) * diabetes mellitus requiring pharmacological treatment or obesity grade ≥ i (bmi ≥30 kg/m2). * patients ≥65 years were included, regardless of other risk factors.

inclusion criteria: patients with sars-cov-2 infection, confirmed by any validated microbiological technique, and with one or more symptoms associated with covid-19 with ≤5 days of evolution and with an oxygen saturation ≥93% breathing room air. in addition, the patients had to present some risk factor for severe disease: chronic heart failure (nyha ≥ 2) arterial hypertension under pharmacological treatment chronic lung disease: copd (bronchitis, emphysema or chronic obstruction) with dyspnoea at least on moderate exertion, or moderate-severe asthma (that required inhaled corticosteroids to control symptoms or had received systemic corticosteroids during the last year due to decompensation) chronic renal failure (glomerular filtration rate <60 ml/min/1.73 m², by ckd- ild) diabetes mellitus requiring pharmacological treatment or obesity grade ≥ i (bmi ≥30 kg/m2). patients ≥65 years were included, regardless of other risk factors.

inclusion criteria: patients with sars-cov-2 infection, confirmed by any validated microbiological technique, and with one or more symptoms associated with covid-19 with ≤5 days of evolution and with an oxygen saturation ≥93% breathing room air. in addition, the patients had to present some risk factor for severe disease: chronic heart failure (nyha ≥ 2) arterial hypertension under pharmacological treatment chronic lung disease: copd (bronchitis, emphysema or chronic obstruction) with dyspnoea at least on moderate exertion, or moderate-severe asthma (that required inhaled corticosteroids to control symptoms or had received systemic corticosteroids during the last year due to decompensation) chronic renal failure (glomerular filtration rate <60 ml/min/1.73 m², by ckd- ild) diabetes mellitus requiring pharmacological treatment or obesity grade ≥ i (bmi ≥30 kg/m2). patients ≥65 years were included, regardless of other risk factors.